NCT06792695 2026-01-20
CANTOR
AstraZeneca
Phase 2 Recruiting
Clinical Trials
48 trialsNCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT03475004 2024-09-19
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT06539559 2024-08-06
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT02363751 2021-03-09
BEVABEL
UNICANCER
Phase 2 Completed
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT01858649 2020-10-22
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT02226289 2020-09-02
BATTLE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT01898130 2019-09-17
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
Phase 2 Completed
NCT01263782 2019-05-15
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT00483834 2019-02-15
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00227019 2017-03-06
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Phase 2 Completed
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01322815 2016-08-15
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
Georgetown University
Phase 2 Terminated
NCT02175446 2016-06-15
GIM11-BERGI
Consorzio Oncotech
Phase 2 Unknown
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00511459 2015-10-29
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Amgen
Phase 2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT00081614 2014-05-16
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00043004 2012-09-24
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00226005 2012-05-09
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase 2 Completed
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01195298 2010-09-06
Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
South Eastern European Research Oncology Group
Phase 2 Unknown
NCT00165568 2009-11-02
Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00120172 2007-11-16
Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
Geriatric Oncology Consortium
Phase 2 Terminated
NCT00385021 2007-11-02
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
Southwestern Regional Medical Center
Phase 2 Terminated